RxDoctor Payments Data

Raju Indukuri, MD

Psychiatry · Brentwood, TNNPI 1831207323

Payments from drug & device makers

$798in general payments, 2019–2025

Across 30 payments — averaging $26.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$113
  • Teva Pharmaceuticals USA, Inc.$106
  • AbbVie$105
  • Otsuka America Pharmaceutical, Inc.$104
  • Orexo US, Inc.$97
  • Tris Pharma Inc$92
  • plus $183 from 7 others

What the payments were for

  • Food & beverage$798100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$798 in reported general payments places this provider in the 65th percentile of 503 psychiatry providers in Tennessee.

See all psychiatry providers in Tennessee

Medicare billing

Part B allowed, 2024
$62,711
Medicare patients
23
Services billed
617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl23$29,525
Aripiprazole35$6,445
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine153$5,364
VyvanseLisdexamfetamine Dimesylate11$4,275
Lurasidone Hcl23$3,184
Desvenlafaxine Succinate ErDesvenlafaxine Succinate22$1,239
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine20$1,222
Duloxetine Hcl52$1,105
Quetiapine Fumarate71$1,060
Methylphenidate Hcl18$755
Buspirone Hcl29$533
Alprazolam172$475
Bupropion XlBupropion Hcl29$444
Trazodone Hcl70$439
Clonazepam89$380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$105$29,52523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 503 psychiatry providers in Tennessee.

Other psychiatry in Brentwood

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →